Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0V8WE
|
|||
| Former ID |
DNC014086
|
|||
| Drug Name |
4-(4,5-dihydrothiazol-2-yl)phenyl butylcarbamate
|
|||
| Synonyms |
CHEMBL457882; AC1MCGW6; 4-(4,5-dihydrothiazol-2-yl)phenyl butylcarbamate; MolPort-002-923-829; HMS1669K08; ZINC4394394; BDBM50274981; CCG-56239; MCULE-6668458781; SR-01000645209-1; [4-(4,5-dihydro-1,3-thiazol-2-yl)phenyl] N-butylcarbamate
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C14H18N2O2S
|
|||
| Canonical SMILES |
CCCCNC(=O)OC1=CC=C(C=C1)C2=NCCS2
|
|||
| InChI |
1S/C14H18N2O2S/c1-2-3-8-16-14(17)18-12-6-4-11(5-7-12)13-15-9-10-19-13/h4-7H,2-3,8-10H2,1H3,(H,16,17)
|
|||
| InChIKey |
OUBMDYCXTDANEM-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Fatty acid amide hydrolase (FAAH) | Target Info | Inhibitor | [1] |
| BioCyc | Anandamide degradation | |||
| KEGG Pathway | Retrograde endocannabinoid signaling | |||
| Panther Pathway | Anandamide degradation | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | The synthesis and biological evaluation of para-substituted phenolic N-alkyl carbamates as endocannabinoid hydrolyzing enzyme inhibitors. Eur J Med Chem. 2009 Jul;44(7):2994-3008. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.